7-bromo-2-methylquinazolin-4(3H)-one | 403850-89-5

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-bromo-2-methylquinazolin-4(3H)-one
• 英文别名: 7-Bromo-2-methylquinazolin-4(3H)-one；7-bromo-2-methyl-3H-quinazolin-4-one
• CAS: 403850-89-5
• 化学式: C₉H₇BrN₂O
• 分子量: 239.071
• InChiKey: CMVNWVONJDMTSH-UHFFFAOYSA-N

物化性质

• 沸点：
  351.2±44.0 °C(Predicted)
• 密度：
  1.72±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  7-bromo-2-methylquinazolin-4(3H)-one 以 乙酸乙酯 、 N,N-二甲基苯胺 为溶剂， 生成 7-溴-4-氯-2-甲基喹唑啉
  参考文献：
  名称：

  Neuropeptide Y antagonists

  摘要：

  喹啉和喹噁啉衍生物可以作为药物制剂的形式使用，作为神经肽Y受体拮抗剂，用于治疗或预防关节炎、心血管疾病、糖尿病、肾功能衰竭、进食障碍和肥胖症。

  公开号：

  US20020052356A1
• 作为产物：
  描述：

  2-氨基-4-溴苯甲酸 在 ammonium hydroxide 作用下， 反应 5.0h， 生成 7-bromo-2-methylquinazolin-4(3H)-one
  参考文献：
  名称：

  [EN] ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS ALLOSTÉRIQUES D'EGFR ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  该披露涉及作为表皮生长因子受体（EGFR）的变构抑制剂的化合物；包括这些化合物的药物组合物；以及治疗或预防激酶介导的疾病，包括癌症和其他增殖性疾病的方法。

  公开号：

  WO2020257632A1

文献信息

• [EN] 2-METHYL-QUINAZOLINES<br/>[FR] 2-MÉTHYL-QUINAZOLINES
  申请人：BAYER PHARMA AG

  公开号：WO2018172250A1

  公开（公告）日：2018-09-27

  The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

  本发明描述了一般式(I)的2-甲基喹唑啉化合物，制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及用于制造药物组合物的该化合物的用途。一般式(I)的2-甲基取代喹唑啉化合物有效且选择性地抑制Ras-Sos相互作用，而不显著靶向EGFR受体。因此，它们对于治疗或预防疾病特别是高增殖性疾病，如癌症作为单一药剂或与其他活性成分组合使用是有用的。
• [EN] BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE POUR TRAITER DES TROUBLES INDUITS PAR GLYTL
  申请人：GLAXO GROUP LTD

  公开号：WO2011012622A1

  公开（公告）日：2011-02-03

  The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

  本发明涉及苯并噁唑酮衍生物，其制备方法，含有它们的药物组合物和药物，以及它们在治疗由GlyT1介导的疾病中的应用，包括神经系统和神经精神疾病，特别是精神病、痴呆或注意力缺陷障碍。
• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• Quinazoline derivatives
  申请人：——

  公开号：US20040029901A1

  公开（公告）日：2004-02-12

  Compounds of formula I 1 as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 , R 2 , R 3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.

  提供具有式I1的化合物，以及其药用可接受的盐和酯，其中R1、R2、R3和A具有规范中给定的含义。这些化合物可用于治疗或预防肥胖。
• [EN] INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] INHIBITEURS D'AMIDE D'HYDROLASE D'ACIDE GRAS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2010118155A1

  公开（公告）日：2010-10-14

  Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.

  本文提供了公式（I）的化合物或其药用可接受的盐、溶剂化合物或前药，或它们的混合物，其中Z1、Z2、X1、X2、X3、R1、R2、R3、m和n在此处被定义。还提供了包括公式I的化合物和药用可接受的赋形剂的药用可接受的组合物。还提供了治疗FAAH介导的疾病的方法，包括向需要的受试者施用本发明化合物或组合物的治疗有效量。